New president of Merck Vaccines
This article was originally published in Scrip
Merck & Co has named Dr Julie Gerberding president of Merck Vaccines, effective January 25th. She will be responsible for the commercialisation of the company's portfolio of vaccines and accelerating Merck's ongoing efforts to broaden access to its vaccines in the developing world. Dr Gerberding led the US Centers for Disease Control and Prevention as director from 2002-09.
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.